There are currently 1574 clinical trials in Baltimore, Maryland looking for participants to engage in research studies. Trials are conducted at various facilities, including Johns Hopkins University, Johns Hopkins Hospital, University of Maryland and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Recruiting
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
02/24/2025
Locations: Pharmasite Research, Inc., Baltimore, Maryland
Conditions: Migraine
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
02/24/2025
Locations: Pharmasite Research, Inc., Baltimore, Maryland
Conditions: Chronic Migraine
A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting
Recruiting
This is an observational study in people with chronic kidney disease (CKD) and type 2 diabetes (T2D) who will be receiving finerenone. Kidneys filter extra water and waste out of the blood and make urine. CKD is a long-term, progressive, decrease in the kidneys' ability to filter the blood properly. In people with T2D, the body does not make enough of a hormone called insulin, or does not use insulin well enough, resulting in high blood sugar levels that can cause damage to the kidneys. As a re... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: University of Maryland Midtown Professionals Group Healthcare, Baltimore, Maryland
Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults
Recruiting
The purpose of this research is to collect blood and urine from adult patients admitted to an intensive care unit. This is to assess the performance of the ProNephro AKI (NGAL) assay (lab test) as an aid to identify patients at risk for acute kidney injury.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
02/24/2025
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Acute Kidney Injury
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Recruiting
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
02/24/2025
Locations: Pharmasite Research, Inc., Baltimore, Maryland
Conditions: Migraine
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
Recruiting
The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematosus in adult patients with moderate to severe symptoms. The main questions it aims to answer are: * How well cenerimod works on top of the treatment already being administered. * How safe cenerimod is for adult patients with Systemic Lupus Erythematosus. Researchers will compare one dose of cenerimod and a placebo to see how well cenerimod works when it is added to the treatment already be... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/24/2025
Locations: Axon Clinical Research -Baltimore, Baltimore, Maryland
Conditions: Lupus Erythematosus, Systemic
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Recruiting
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Gender:
ALL
Ages:
60 years and above
Trial Updated:
02/24/2025
Locations: The Retina Care Center (01-023), Baltimore, Maryland
Conditions: Geographic Atrophy
Evaluate the Safety and Effectiveness of the Polymotion Hip Resurfacing (PHR) System Compared to Total Hip Arthroplasty
Recruiting
The goal of this clinical trial is to evaluate the safety and effectiveness of the Polymotion Hip Resurfacing (PHR) System compared to total hip arthroplasty, for adults who require hip resurfacing arthroplasty due to 1) non-inflammatory arthritis (degenerative joint disease) such as osteoarthritis, traumatic arthritis, or 2) mild dysplasia/developmental dislocation of the hip (DDH) up to Crowe Grade 1.
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
02/24/2025
Locations: Sinai Hospital / LifeBridge Health, Baltimore, Maryland
Conditions: Osteoarthritis of the Hip, Degenerative Joint Disease of Hip, Dysplasia; Hip
Study of M5049 in DM and PM Participants (NEPTUNIA)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of orally administered M5049 in idiopathic inflammatory myopathies, specifically dermatomyositis (DM) and polymyositis (PM) participants for 24 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/24/2025
Locations: Johns Hopkins University - Department of Medicine, Division of Rheumatology, Baltimore, Maryland
Conditions: Dermatomyositis, Polymyositis
American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry
Recruiting
The purpose of this study is to create a registry to provide insight into treatment selection and treatment outcome of pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical interventions. The investigators seek a better understanding of the uses of ablation in the treatment of unresectable soft tissue pancreatic tumors and the limitations, concerns and complications that earlier users hav... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/23/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Pancreatic Cancer
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
Recruiting
This double-blind, randomized, placebo-controlled, multinational, multicenter, parallel-group, Phase 3, 2-arm, study will investigate the efficacy and safety of belumosudil compared with placebo, both administered on top of azithromycin and standard-of-care regimen of immunosuppression in male or female participants at least 1 year after bilateral lung transplant, who are at least 18 years of age and who have evidence of progressive CLAD despite azithromycin therapy. Study details include: The... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: University of Maryland School of Medicine - Baltimore- Site Number : 8400009, Baltimore, Maryland +1 locations
Conditions: Lung Transplant Rejection
Rilonacept in Subjects with Cardiac Sarcoidosis
Recruiting
The primary objective of this study is to evaluate the effect of rilonacept, added to standard therapy and compared with standard therapy alone, on improvement in myocardial inflammation in subjects with cardiac sarcoidosis after 24 weeks of therapy.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/21/2025
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Cardiac Sarcoidosis